Melanotan I
Also known as: Melanotan I, Afamelanotide, Scenesse
A selective MC1R-favoring melanocortin agonist approved (as Scenesse/afamelanotide) to reduce phototoxicity in erythropoietic protoporphyria. More selective for pigmentation than Melanotan II.
Last updated
Mechanism of Action
Melanotan I (afamelanotide) is a linear alpha-MSH analog that preferentially activates the MC1R receptor on melanocytes, stimulating eumelanin synthesis and skin darkening. Its greater selectivity for MC1R over MC4R means it produces fewer libido and appetite effects than Melanotan II. The increased melanin provides photoprotection, which is the basis of its approval for a rare light-sensitivity disorder.
- Half-life
- Short in free form; clinical product uses a slow-release implant
- Administration Routes
- subcutaneous
- Research Status
- Clinical
Reported Benefits
- Selective pigmentation effect with fewer MC4R side effects
- FDA/EMA-approved (as Scenesse) for erythropoietic protoporphyria
- Increases photoprotective melanin
- Reduces phototoxic reactions in light-sensitivity disorders
- More predictable side-effect profile than MT-II
Potential Side Effects
- Darkening of moles and new pigmented spots
- Mild nausea or headache
- Implant-site reactions (clinical form is a subcutaneous implant)
- Fatigue in some users
Common Dosing
The approved clinical product is a 16 mg controlled-release subcutaneous implant administered periodically. Stated as the labeled clinical form.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- History of melanoma or atypical mole syndrome
- Pregnancy or breastfeeding
- Severe hepatic impairment (consult labeling)
- View
Afamelanotide for Erythropoietic Protoporphyria
2015
- View
An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria
2009
- View
Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers
2004
- View
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria
2021